Novel use for pde5 inhibitors

A method of treatment or prophylaxis of a disease associated with or based on impairment or dysfunction of cerebral vascular reactivity selected from the group consisting of sepsis associated encephalopathy, sepsis, toxic encephalopathy, encephalopathy associated with autoimmune thyroiditis, autoimmune thyroiditis, cerebral microangiopathy, hypercholesterolemia and hypertriglyceridemia in a patient afflicted with such disease comprising the step of administering a pharmacologically tolerable and therapeutically effective amount of a PDE5 inhibitor to the patient.

The method according to claim 3, wherein the PDE5 inhibitor is selected from the group consisting of sildenafil, vardenafil, tadalafil, a pharmaceutically acceptable salt thereof and a solvate of the pharmaceutically acceptable salt thereof.

The method according to claim 4, wherein the PDE5 inhibitor is selected from the group consisting of sildenafil citrate, vardenafil hydrochloride, the trihydrate of vardenafil hydrochloride and vardenafil dihydrochloride.